Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

19 Feb 2013

Abstract excerpt

The nonstructural 5A (NS5A) protein is a target for drug development against hepatitis C virus (HCV). Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration. However, NS5A has no known enzymatic functions, making it difficult to understand daclatasvir's mode of action (MOA) and to estimate its antiviral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Hepatitis C virus research
Share to Liver Disease Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23431163
DOI: 10.1073/pnas.1203110110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifePMID 23431163Read ↗

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.Semantic proximity Read ↗

Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein MechanismsSemantic proximity Read ↗

Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.Semantic proximity Read ↗

A perspective on modelling hepatitis C virus infectionSemantic proximity Read ↗

What drives the dynamics of HBV RNA during treatment?Semantic proximity Read ↗

Disentangling the lifespans of hepatitis C virus-infected cells and intracellular vRNA replication-complexes during direct-acting anti-viral therapy.Semantic proximity Read ↗

Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.Semantic proximity Read ↗

A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis BSemantic proximity Read ↗

Mathematical modeling of plus-strand RNA virus replication to identify broad-spectrum antiviral treatment strategiesSemantic proximity Read ↗

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.Semantic proximity Read ↗

Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agentsSemantic proximity Read ↗

Replication Vesicles are Load- and Choke-Points in the Hepatitis C Virus LifecycleSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.